Gregorii Tochilnikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gregorii Tochilnikov has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina Sinitsyna
Institute of Chemistry, Saint-Petersburg State University, Peterhof, 198504 St. Petersburg, Russia
1 shared publication - Elena Yu. Tupikina
St. Petersburg State University, Institute of Chemistry, Universitetskii pr. 26, 198504 St. Petersburg, Russian Federation
1 shared publication - Evgenia Korzhikova-Vlakh
Institute of Chemistry, Saint-Petersburg State University, Universitetskiy pr. 26, 198504 St. Petersburg, Russia
1 shared publication - Irina Bagaeva
Institute of Chemistry, Saint-Petersburg State University, Universitetskiy pr. 26, 198504 St. Petersburg, Russia
1 shared publication - Mikhail Orlov
Institute of Chemistry, Saint-Petersburg State University, Universitetskiy pr. 26, 198504 St. Petersburg, Russia
1 shared publication - Seregey A. Silonov
Laboratory of Structural Dynamics, Stability and Folding of Proteins, Institute of Cytology, Russian Academy of Sciences, 4 Tikhoretsky Ave., 194064 St. Petersburg, Russia
1 shared publication
Latest Publications
- Open Access
mPEG-b-PCL-Based Nanoformulations of Aziridine-Functionalized 1,3,5-Triazine Derivative for Cancer Treatment
Developing nanoformulations of antitumor drugs represents a critical priority in addressing key challenges of free drug administration such as low therapeutic efficacy, poor bioavailability, and severe side effects, including high systemic toxicity. In this study, mPEG-b-PCL block copolymers of different molecular weights were synthesized and applied to develop nanoformulations of the antitumor aziridine-functionalized 1,3,5-triazine derivative, dioxadet (DOD) via nanoprecipitation. The resulting DOD-loaded nanoparticles exhibited optimal characteristics for intravenous administration, and high encapsulation efficiency. The effect of mPEG-b-PCL molecular weight on drug encapsulation and release was investigated, and the results were elucidated through computational analysis of the molecular binding mechanism between DOD and PCL. Release profiles showed a sustained biphasic pattern. Determination of DOD concentration in blood of healthy rats indicated that the nanoformulation extended DOD’s circulation time. The empty nanoparticles were well-tolerated by both normal and cancer cells. The nanoformulation maintained inhibitory activity against A549 cells with an IC50, comparable to that of free DOD. The antitumor efficacy and reduced toxicity of the optimized nanoformulation were demonstrated in mice using two ascitic tumor models (Ehrlich ascites carcinoma and L1210 lymphoid leukemia) and one solid tumor model (Lewis lung epidermoid carcinoma) with the greatest therapeutic effect observed against the solid tumor.
Open AccessmPEG-b-PCL-Based Nanoformulations of Aziridine-Functionalized 1,3,5-Triazine Derivative for Cancer Treatment
Developing nanoformulations of antitumor drugs represents a critical priority in addressing key challenges of free drug administration such as low therapeutic efficacy, poor bioavailability, and severe side effects, including high systemic toxicity. In this study, mPEG-b-PCL block copolymers of different molecular weights were synthesized and applied to develop nanoformulations of the antitumor aziridine-functionalized 1,3,5-triazine derivative, dioxadet (DOD) via nanoprecipitation. The resulting DOD-loaded nanoparticles exhibited optimal characteristics for intravenous administration, and high encapsulation efficiency. The effect of mPEG-b-PCL molecular weight on drug encapsulation and release was investigated, and the results were elucidated through computational analysis of the molecular binding mechanism between DOD and PCL. Release profiles showed a sustained biphasic pattern. Determination of DOD concentration in blood of healthy rats indicated that the nanoformulation extended DOD’s circulation time. The empty nanoparticles were well-tolerated by both normal and cancer cells. The nanoformulation maintained inhibitory activity against A549 cells with an IC50, comparable to that of free DOD. The antitumor efficacy and reduced toxicity of the optimized nanoformulation were demonstrated in mice using two ascitic tumor models (Ehrlich ascites carcinoma and L1210 lymphoid leukemia) and one solid tumor model (Lewis lung epidermoid carcinoma) with the greatest therapeutic effect observed against the solid tumor.